as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 28 Sep 2026
₹2,435.6
Change
-39.3 (-1.59%)
Open
₹2,474.9
Prev. Close
₹2,474.9
Day High
₹2,488.3
Day Low
₹2,430.3
Volume Analysis
Traded
388,832
Delivered
229,158
Delivery %
58.93%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (26.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year revenue growth (17.7%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,530.5 | ₹2,509.4 | ₹2,472.5 | ₹2,451.4 | ₹2,414.5 | ₹2,393.4 | ₹2,356.5 |
| Fibonacci | ₹2,509.4 | ₹2,487.24 | ₹2,473.56 | ₹2,451.4 | ₹2,429.24 | ₹2,415.56 | ₹2,393.4 |
| Camarilla | ₹2,451.55 | ₹2,446.23 | ₹2,440.92 | ₹2,451.4 | ₹2,430.28 | ₹2,424.97 | ₹2,419.65 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+12.52%
1 Week
-1.79%
1 Month
+2.21%
3 Months
-2.2%
6 Months
+21.87%
1 Year
-1.07%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹641.75
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
12.16%
Net margin 14.03% × asset turnover 0.51x × equity multiplier 1.7x
Company Overview
Sector
Healthcare
Market Cap
₹102,225 Cr
P/E (TTM)
47.9
ROE
13.1%
Book Value
₹395.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Mankind Pharma Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (95/100), while Valuation (11/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (26.0%); promoter holding is falling. Strong 3-year revenue growth (17.7%).
TopFund Score — Fundamentals Quality
69/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 28 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- −Promoter holding has decreased over last 3 years: -3.87%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Postal ballot passed appointing Anish Vanraj Bafna as Non-Executive Independent Director from August 10, 2026.
Niche99 assigned Mankind Pharma 68.21 ESG rating in Leader category for FY 2025-26.
Mankind Pharma to participate in three investor conferences on 17, 18, and 21 September 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,579 | 2,708 | 2,607 | 2,422 | 2,868 | 3,061 | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | 4,031 |
| Expenses + | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,214 | 2,383 | 2,396 | 2,724 | 2,776 | 2,648 | 2,513 | 2,974 |
| Operating Profit | 655 | 683 | 606 | 586 | 672 | 847 | 816 | 683 | 847 | 921 | 919 | 930 | 1,056 |
| OPM % | 25.0% | 25.0% | 23.0% | 24.0% | 23.0% | 28.0% | 26.0% | 22.0% | 24.0% | 25.0% | 26.0% | 27.0% | 26.0% |
| Other Income + | 63 | 63 | 75 | 94 | 108 | 109 | 87 | 249 | 83 | 94 | -31 | 94 | 49 |
| Interest | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 | 110 |
| Depreciation | 87 | 96 | 110 | 100 | 103 | 100 | 187 | 231 | 219 | 222 | 223 | 223 | 226 |
| Profit before tax | 624 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 540 | 624 | 509 | 659 | 769 |
| Tax % | 21.0% | 20.0% | 18.0% | 17.0% | 18.0% | 22.0% | 22.0% | 17.0% | 18.0% | 17.0% | 19.0% | 15.0% | 25.0% |
| Net Profit + | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 |
| EPS in Rs | 12 | 13 | 11 | 12 | 13 | 16 | 9 | 10 | 11 | 12 | 10 | 13 | 14 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,334 | 5,865 | 6,214 | 7,782 | 8,749 | 10,260 | 12,207 | 14,278 | 14,738 |
| Expenses + | 2,748 | 4,427 | 4,565 | 5,791 | 6,848 | 7,743 | 9,182 | 10,653 | 10,911 |
| Operating Profit | 586 | 1,438 | 1,649 | 1,991 | 1,902 | 2,517 | 3,026 | 3,625 | 3,827 |
| OPM % | 18.0% | 25.0% | 27.0% | 26.0% | 22.0% | 25.0% | 25.0% | 25.0% | 26.0% |
| Other Income + | 76 | 122 | 183 | 210 | 141 | 295 | 548 | 238 | 207 |
| Interest | 2 | 23 | 21 | 60 | 46 | 34 | 432 | 644 | 579 |
| Depreciation | 39 | 99 | 119 | 167 | 326 | 378 | 621 | 886 | 893 |
| Profit before tax | 621 | 1,438 | 1,692 | 1,975 | 1,671 | 2,399 | 2,521 | 2,333 | 2,562 |
| Tax % | 29.0% | 27.0% | 24.0% | 26.0% | 22.0% | 19.0% | 20.0% | 17.0% | — |
| Net Profit + | 445 | 1,056 | 1,293 | 1,453 | 1,310 | 1,942 | 2,011 | 1,938 | 2,068 |
| EPS in Rs | 219 | 26 | 32 | 36 | 32 | 48 | 48 | 46 | 49 |
| Dividend Payout % | 0.0% | 0.0% | 24.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 2,035 | 3,445 | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 | 16,259 |
| Borrowings + | 0 | 131 | 241 | 873 | 170 | 207 | 8,511 | 6,312 |
| Other Liabilities + | 968 | 1,449 | 1,397 | 2,080 | 2,080 | 2,313 | 4,808 | 5,143 |
| Total Liabilities | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 27,652 | 27,755 |
| Fixed Assets + | 316 | 1,600 | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 | 18,620 |
| CWIP | 47 | 317 | 372 | 701 | 550 | 282 | 826 | 1,128 |
| Investments | 959 | 829 | 1,512 | 1,109 | 1,346 | 2,568 | 2,042 | 1,985 |
| Other Assets + | 1,700 | 2,319 | 2,811 | 3,709 | 3,538 | 4,488 | 5,780 | 6,022 |
| Total Assets | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 27,652 | 27,755 |
| Equity Capital | 20 | 40 | 40 | 40 | 40 | 40 | 41 | 41 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | — | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 | 3,121 |
| Cash from Investing Activity + | — | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 | -181 |
| Cash from Financing Activity + | — | -531 | -8 | 605 | -740 | 5 | 10,233 | -2,953 |
| Net Cash Flow | — | 103 | -92 | 156 | 22 | 77 | 22 | -12 |
| CFO/OP | — | 97 | 96 | 71 | 112 | 103 | 98 | 102 |
| Free Cash Flow | — | 853 | 826 | -1,423 | 987 | 1,771 | 1,895 | 2,387 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 14.76% | 6.97% | 4.1% | 3.61% | 2.86% | 2.89% | 2.89% | 2.75% | 2.57% | 2.75% | 2.63% | 2.53% |
| Promoters | 76.5% | 76.5% | 74.88% | 74.87% | 74.87% | 72.71% | 72.7% | 72.67% | 72.67% | 72.66% | 72.66% | 72.63% |
| FII | 4.18% | 6.74% | 9.87% | 11.58% | 12.37% | 13.34% | 12.92% | 13.07% | 12.83% | 11.34% | 10.24% | 9.45% |
| DII | 4.56% | 9.78% | 11.14% | 9.94% | 9.91% | 11.05% | 11.47% | 11.5% | 11.91% | 13.26% | 14.46% | 15.39% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Mankind Pharma Limited (this stock) | 102,225 | 47.9 | 6.27 | 13.1% |
| Dr. Reddy S Laboratories | 101,096 | 31.4 | 2.67 | 11.2% |
| Aurobindo Pharma Ltd | 98,939 | 26.2 | 2.64 | 10.1% |
| Max Healthcare Ins Ltd | 98,694 | 65.9 | 9.22 | 14.7% |
| Laurus Labs Limited | 108,438 | 99.2 | 20.44 | 18.3% |
| Lupin Limited | 95,788 | 16.1 | 4.26 | 28.7% |
| Manipal Health Enterpri L | 95,694 | 108.0 | — | 12.7% |
Which Mutual Funds Hold Mankind Pharma Limited?
Frequently Asked Questions about Mankind Pharma Limited
Mankind Pharma Limited (MANKIND) closed at ₹2,435.6 on NSE on 28 September 2026, down 39.3 (1.59%) from the previous close.
Mankind Pharma Limited trades on the NSE (National Stock Exchange of India) under the symbol MANKIND.
Mankind Pharma Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 47.9.
Mankind Pharma Limited has a dividend yield of 0.04%.
Mankind Pharma Limited's 52-week high is ₹2,642.0 and its 52-week low is ₹1,910.0.
Mankind Pharma Limited has a market capitalisation of ₹102,225 crore.
Mankind Pharma Limited has a TopFund Quality Score of 69/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Mankind Pharma Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.